PPARδ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-21. Numbers and descriptions here follow the published literature rather than marketing material.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
The safety of a medical product concerns the medical risk to the subject, usually assessed in a clinical trial by laboratory tests (including clinical chemistry and haematology), vital signs, clinical adverse events (diseases, signs and symptoms), and other special safety tests (e.g. ECGs, ophthalmology). The tolerability of the medical product represents the degree to which overt adverse effects can be tolerated by the subject. (ICH E9) Screening trials
=== Versions === The same scale has been validated in Spanish, Brazilian Portuguese, and Polish versions. A version has also been designed and validated for children. More recently, in September 2011, a modified version of the scale was validated using a criterion of self-assessment for ages six–eight years of age. A version of the scale was developed into a chart suitable for use on US television by Gary Kahan of NewYork–Presbyterian Hospital.
== Causes == It is mainly unknown what causes sJIA. There have been reports of seasonal fluctuations in the incidence of sJIA in some places but not in others. Although it has frequently been claimed that infectious organisms cause the condition to manifest, microbiologic and virologic analyses are unable to pinpoint a single agent as the cause. Since a negative septic screen is required for the diagnosis, sJIA is not an infectious disease by definition. There is evidence that suggests a genetic predisposition plays a role in the etiology of sJIA.
Sources: en.wikipedia.org
At the beginning of June 1976, the King visited the United States and in his speech before Congress, of whose exact content Arias Navarro was not aware, he ratified his commitment to provide Spain with a full democracy. Juan Carlos announced the Crown's will to "ensure the access to power of the different government alternatives, according to the freely expressed wishes of the Spanish people". A month and a half earlier, Newsweek magazine had claimed that King Juan Carlos had told one of its journalists ─ which was never denied ─ that "Arias was an unmitigated disaster". Around the same time Arias Navarro had made a statement on television in which he had made harsh attacks on the democratic opposition, while his relations with the king had deteriorated to the point that Arias had confessed to one of his closest collaborators: "It happens to me like with children; I can't stand him for more than ten minutes". After commenting to Areilza "this cannot go on, at the risk of losing everything ...", Juan Carlos demanded Arias Navarro on July 1 to present his resignation, which he did immediately. A few days later, Torcuato Fernández Miranda succeeded in getting the Council of the Realm to include among the three aspirants for President of the Government the "king's candidate": Adolfo Suárez, a "blue reformist" who had not stood out too much until then. Suárez's appointment caused enormous bewilderment and disappointment among the democratic opposition and diplomatic circles, as well as in newspaper editorial offices.
== Function == The function galectin-7 has recently been found to be a critical role in is with skin tissue linking to skin cancers because of its involvement with apoptosis from the LGALS7 gene that the protein is produced from, though it still is involved with the oral cavity, esophagus, epidermis, and cornea, with skin cancer being the most notable one. During skin repair, cell migration is the process by which cells close a wound which includes the epidermal keratinocytes migration which re-established the skin barrier, re-epithelialization. The protein's involvement, if deficient, can result in a defect of cell migration leading to less proficient skin repair as well. Re-epithelialization, skin repair, the regulation of cell migration, and cell adhesion is also expressed within skin tumors and still needs to be better researched as its abnormal expression in carcinomas, cancer progression, and metastasis is still not understood in terms of its function. While the protein's function in the nucleus is still unknown, the diverse studies for the cellular function in mitochondria and cytosol link pathways to regulation of keratinocyte and differentiation while also having a mutation bind to a hot spot called the galectin-7 promoter. Galectin-7 regulates cell growth, cell differentiation, and apoptosis in epithelial maintenance roles but there are still many unknowns when it comes to this protein in its role of cellular processes.
==== Prize ==== The French government had offered over 320,000 Francs as a reward to whoever could discover a cure for the blight. Having reportedly been the first to suggest the possibility of using the resistant American rootstock, Leo Laliman tried to claim the money, but the French government refused to award it, with the rationale that he had not cured the blight, but rather stopped it from occurring. However, there may have been other reasons for the government denying Laliman the prize: he was mistrusted by several notable parties, and he was thought by many to have originally introduced the pest.
Sources: en.wikipedia.org
Marshall (born 1944), American chemist, co-inventor of Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry Archer John Porter Martin (1910–2002), British physical chemist, 1952 Nobel Prize in Chemistry for the invention of partition chromatography Martinus van Marum (1750–1837), Dutch physician, inventor, scientist and teacher, which created the "large electricity machine" Elmer McCollum (1879–1967), American biochemist, known for work of diet on health Edwin McMillan (1907–1991), American physicist, the first to produce a transuranium element, neptunium, 1951 Nobel Prize in Chemistry Lise Meitner (1878–1968), Austrian and Swedish nuclear physicist instrumental in the discovery of nuclear fission Dmitri Ivanovich Mendeleev (1834–1907), Russian chemist, creator of the Periodic table of elements Maud Menten (1879–1960). Canadian biochemist known for early work on enzyme kinetics John Mercer (1791–1866), British dye and fabric chemist who developed mercerisation, a process for treating cotton Robert Bruce Merrifield (1921–2006), solid-phase chemist, 1984 Nobel Prize in Chemistry Julius Lothar Meyer (1830–1895), German chemist, one of the pioneers in developing the earliest versions of the periodic table of the chemical elements Viktor Meyer (1848–1897), German organic and inorganic chemist, known for work on vapour densities
== Lecturer == From 2005 to 2013, he served as a neurophysiology researcher at the University of Ulm.[23] In 2014, he received a lifelong appointment as Visiting Professor at the Instituto Universitario de Ciencias de la Salud, Buenos Aires.[17] Since 2019, Schleip has been a Research Associate and, since 2024, a Senior Scientist at the professorship of conservative and rehabilitative orthopaedics in the TUM School of Medicine & Health at the Technical University of Munich.[23]
A complicating factor is that a single ion channel may have multiple internal "gates" that respond to changes in Vm in opposite ways, or at different rates. For example, although raising Vm opens most gates in the voltage-sensitive sodium channel, it also closes the channel's "inactivation gate", albeit more slowly. Hence, when Vm is raised suddenly, the sodium channels open initially, but then close due to the slower inactivation. The voltages and currents of the action potential in all of its phases were modeled accurately by Alan Lloyd Hodgkin and Andrew Huxley in 1952, for which they were awarded the Nobel Prize in Physiology or Medicine in 1963. However, their model considers only two types of voltage-sensitive ion channels, and makes several assumptions about them, e.g., that their internal gates open and close independently of one another. In reality, there are many types of ion channels, and they do not always open and close independently.
The description of feathered dinosaurs has not been without controversy in general; perhaps the most vocal critics have been Alan Feduccia and Theagarten Lingham-Soliar, who have proposed that some purported feather-like fossils are the result of the decomposition of collagenous fiber that underlaid the dinosaurs' skin, and that maniraptoran dinosaurs with vaned feathers were not actually dinosaurs, but convergent with dinosaurs. However, their views have for the most part not been accepted by other researchers, to the point that the scientific nature of Feduccia's proposals has been questioned. Archaeopteryx was the first fossil found that revealed a potential connection between dinosaurs and birds. It is considered a transitional fossil, in that it displays features of both groups. Brought to light just two years after Charles Darwin's seminal On the Origin of Species (1859), its discovery spurred the nascent debate between proponents of evolutionary biology and creationism. This early bird is so dinosaur-like that, without a clear impression of feathers in the surrounding rock, at least one specimen was mistaken for the small theropod Compsognathus. Since the 1990s, a number of additional feathered dinosaurs have been found, providing even stronger evidence of the close relationship between dinosaurs and modern birds. Many of these specimens were unearthed in the lagerstätten of the Jehol Biota.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.